G2211 and Your wRVU Pay: What Primary Care Physicians Need to Know (2026)

Why CMS created G2211

The standard outpatient E/M codes — 99212 through 99215 — measure the complexity of a single encounter. They do not distinguish between a one-time urgent care visit and a visit that is the fourteenth in a five-year relationship with a patient managing four chronic conditions. CMS recognized that this gap left a category of longitudinal physician work unmeasured and unreimbursed.

Beginning January 1, 2024, CMS introduced G2211, an add-on HCPCS code for office and outpatient E/M visits that captures the additional work involved in being the continuing focal point for a patient's overall medical care. The code is intended for physicians — most commonly in primary care and other longitudinal specialties — whose practice patterns involve ongoing management of complex or multiple chronic conditions across visits, not isolated single-problem encounters.

G2211 does not replace or restructure any existing visit code. It appends to a standard E/M code when the clinical relationship qualifies, adding a separately measurable unit of physician work to what is already credited.

The wRVU: 0.33 per qualifying visit

Each time G2211 is billed with an eligible visit, it adds 0.33 work RVUs to your production for that encounter. This value has been unchanged since the code launched and remains 0.33 in the 2026 CMS Physician Fee Schedule.

For comparison: a level-4 established office visit (a moderate-complexity visit) carries 1.92 wRVUs. Appending G2211 brings that encounter to 2.25 wRVUs — an increase of about 17% for that single visit. A level-3 established visit at 1.30 wRVUs becomes 1.63 with the add-on.

G2211 can be appended to standard office and outpatient E/M codes — new patient codes 99202 through 99205 and established patient codes 99211 through 99215 — when the visit reflects an ongoing longitudinal care relationship and the same physician or physician group is acting as the patient's primary care focal point for their overall medical needs.

Two expansions are in effect for 2026 that broaden when the code applies:

• Preventive visits: When G2211 launched in 2024, CMS prohibited billing it on any day modifier 25 appeared on the E/M code — which blocked same-day billing during Annual Wellness Visits and other Medicare preventive services. Effective January 1, 2025, CMS reversed that prohibition, but only for a specific scenario: G2211 may now be billed when the E/M base code carries modifier 25 and the same-day additional service is a Medicare Part B preventive service (Annual Wellness Visit, Initial Preventive Physical Examination, or vaccine administration). Documentation of medical necessity for both services is required. The reversal does not apply when modifier 25 appears for other reasons, such as a separate acute visit on the same day as a non-preventive procedure.
• Home and residence codes: Since January 1, 2026, G2211 is also payable with home and residence visit codes (99341, 99342, 99344, 99345, 99347, 99348, 99349, and 99350).

The code is not separately payable for inpatient hospital, emergency department, or skilled nursing facility encounters. It is also excluded at Federally Qualified Health Centers and Rural Health Clinics, where global encounter rates already incorporate this type of work.

Which payers cover G2211 — and which don't

Coverage varies significantly by payer type, and this determines how much of your G2211 billing actually translates into revenue and recorded wRVU production credit.

Traditional Medicare

G2211 is covered under the Medicare Physician Fee Schedule. It is a separately paid line item when appended to a qualifying E/M code by a physician or other eligible clinician billing under Medicare Part B.

Medicare Advantage

Major Medicare Advantage carriers — including Aetna, Anthem, Cigna, Humana, and UnitedHealthcare — confirmed coverage of G2211 for their Medicare Advantage plans. Coverage across Blue Cross Blue Shield Medicare Advantage affiliates varies by state.

Commercial plans

This is where the picture becomes considerably more complicated. Many large commercial carriers either do not separately reimburse G2211 or have stopped paying it, typically on the grounds that the complexity it represents is already bundled into the standard E/M payment. UnitedHealthcare stopped paying G2211 for its commercial (employer-sponsored) plans effective September 1, 2024, though it continues to cover the code under Medicare Advantage. Multiple Blue Cross Blue Shield affiliates and other commercial carriers have similarly treated G2211 as non-payable for their commercial products.

The AAFP, which tracks payer decisions in an ongoing national G2211 coverage matrix, characterizes commercial plan coverage as inconsistent and generally limited. What this means for your practice: a high-Medicare or Medicare-Advantage payer mix will realize more of G2211's production value than a practice where most patients are commercially insured.

What G2211 adds to annual production — in numbers

At 0.33 wRVUs per qualifying visit, the impact on annual production depends on utilization rate and payer mix. Some context from published analyses:

To put the 50% utilization scenario in context: a family medicine physician generating 4,500 wRVUs per year who adds 350 wRVUs from G2211 sees roughly a 7–8% increase in measured production. At an illustrative rate of $55 per wRVU, that is about $19,250 in additional production-based pay per year — if your employer's compensation plan credits those wRVUs at face value and the visits were paid by covered payers. (Actual compensation rates vary by specialty, market, and practice model; $55 is used here purely for illustration.)

When CMS introduced G2211, it projected adoption would reach 38–54% of eligible encounters. Actual uptake fell well short of that in the first year: one widely cited analysis of more than 20,000 physicians found G2211 was appended to only 5.2% of eligible E/M encounters in 2024, with about a third of eligible physicians billing the code at all. Other data sets tracked adoption growing from roughly 10% early in 2024 toward 19% by year-end. Whichever figure is closer to your own organization's billing rate, actual adoption has so far been well below CMS projections.

How employers are handling it in compensation plans

This is the practical question for most physicians: if my wRVU production increases because my group is billing G2211, how does that affect my pay?

The answer is not uniform across health systems. AMGA Consulting and ECG Management, analyzing health system responses, found three distinct approaches in practice:

Wait-and-see

The employer has physicians bill G2211 where appropriate, tracks the resulting wRVU data, and defers a final compensation plan decision until year-end or until the revenue picture becomes clearer. This leaves the production impact temporarily unresolved from a pay standpoint.

Exclude G2211 wRVUs from productivity

Some health systems credit G2211 wRVUs in production tracking but calculate bonus triggers and compensation using a methodology that strips out the G2211 component — or raise the productivity threshold to account for the expected additional production. In this approach, billing the code does not directly increase pay.

Do not bill at all

Some groups chose not to implement G2211 billing in the first year, primarily to avoid the operational and compensation-plan complexity of recalibrating physician pay in response to a new code with uncertain payer adoption.

Why the hesitation? The economics matter here. G2211 adds wRVUs and, where covered payers reimburse it, some additional revenue. But if a primary care physician adds 350 wRVUs per year from G2211 and only 30% of those visits were Medicare (with commercial plans not paying), the revenue increase is modest while the compensation cost at a typical $/wRVU rate is not. AMGA noted that this mismatch could create a net cost increase for health systems that simply credit all G2211 wRVUs at the standard rate without offsetting revenue growth.

So far, the low actual adoption rate has meant a limited aggregate impact on physician production benchmarks. ECG Management's data showed the median benchmark shift from G2211 was less than 1% across all specialties (about 1.1% for primary care). As adoption grows and commercial coverage evolves, this picture could change.

What to ask about your own arrangement

Before drawing conclusions about how G2211 will or won't change your paycheck, a few questions are worth asking directly:

• Is your group billing G2211? Not all organizations have implemented it. Ask your billing department which payers they are billing and for what patient types.
• Does your compensation plan credit G2211 wRVUs toward your production? If the code is billed but excluded from the productivity calculation that determines your bonus, the wRVU impact is invisible to your paycheck.
• Is your threshold or per-wRVU rate being adjusted in response? If G2211 wRVUs are credited but your threshold has been raised to absorb them, ask for the specific adjustment methodology and how your base benchmark was determined.
• What is your payer mix? If most of your patients are commercially insured, G2211 may generate fewer paid claims than expected, reducing the revenue basis your employer might use to justify crediting the wRVUs.

If you are negotiating or renegotiating a contract at an organization that has already implemented G2211 billing, it is worth asking whether G2211 wRVUs are included in the production data used to set your threshold, and if so, whether the threshold has been adjusted relative to the prior year's benchmark.